Bristol-Myers Squibb [BMY] vs Amgen [AMGN] Detailed Stock Comparison

Bristol-Myers Squibb Company

NYSE
Loading...

Amgen Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Bristol-Myers Squibb Company wins in 13 metrics, Amgen Inc. wins in 8 metrics, with 0 ties. Bristol-Myers Squibb Company appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Bristol-Myers Squibb Company Amgen Inc. Better
P/E Ratio (TTM) 17.06 24.22 Bristol-Myers Squibb Company
Price-to-Book Ratio 6.51 21.46 Bristol-Myers Squibb Company
Debt-to-Equity Ratio 254.98 640.28 Bristol-Myers Squibb Company
PEG Ratio 0.01 0.22 Bristol-Myers Squibb Company
EV/EBITDA 8.20 13.97 Bristol-Myers Squibb Company
Profit Margin (TTM) 14.64% 20.98% Amgen Inc.
Operating Margin (TTM) 28.16% 30.55% Amgen Inc.
EBITDA Margin (TTM) 28.16% 30.55% Amgen Inc.
Return on Equity 40.44% 106.10% Amgen Inc.
Return on Assets (TTM) 10.29% 7.93% Bristol-Myers Squibb Company
Free Cash Flow (TTM) $12.85B $8.10B Bristol-Myers Squibb Company
Dividend Yield 5.82% 3.30% Bristol-Myers Squibb Company
1-Year Return 18.43% 16.87% Bristol-Myers Squibb Company
Price-to-Sales Ratio (TTM) 2.50 5.06 Bristol-Myers Squibb Company
Enterprise Value $156.74B $232.21B Amgen Inc.
EV/Revenue Ratio 3.25 6.32 Bristol-Myers Squibb Company
Gross Profit Margin (TTM) 67.23% 69.84% Amgen Inc.
Revenue per Share (TTM) $24 $68 Amgen Inc.
Earnings per Share (Diluted) $3.46 $14.24 Amgen Inc.
Beta (Stock Volatility) 0.27 0.47 Bristol-Myers Squibb Company
Short % of Float 1.54% 2.60% Bristol-Myers Squibb Company

Bristol-Myers Squibb Company vs Amgen Inc. Stock Performance Analysis

Loading Price Chart...

BMY
AMGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Bristol-Myers Squibb Company0.48%-6.15%-5.09%-12.64%12.87%1.87%
Amgen Inc.3.03%-2.29%1.36%-14.89%-2.98%0.19%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Bristol-Myers Squibb Company18.43%-12.92%-11.95%-21.55%104.36%126.28%
Amgen Inc.16.87%54.44%42.20%111.56%473.85%386.83%

Performance & Financial Health Analysis: Bristol-Myers Squibb Company vs Amgen Inc.

MetricBMYAMGN
Market Information
Market Cap i$119.87B$187.93B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i8,535,0022,431,753
90 Day Avg. Volume i11,824,3572,596,291
Last Close$54.72$338.22
52 Week Range$42.52 - $62.89$267.83 - $391.29
% from 52W High-12.99%-13.56%
All-Time High$81.44 (Nov 28, 2022)$391.29 (Mar 02, 2026)
% from All-Time High-32.81%-13.56%
Growth Metrics
Quarterly Revenue Growth0.01%0.09%
Quarterly Earnings Growth14.10%1.13%
Financial Health
Profit Margin (TTM) i0.15%0.21%
Operating Margin (TTM) i0.28%0.31%
Return on Equity (TTM) i0.40%1.06%
Debt to Equity (MRQ) i254.98640.28
Cash & Liquidity
Book Value per Share (MRQ)$9.07$16.07
Cash per Share (MRQ)$5.24$16.94
Operating Cash Flow (TTM) i$14.16B$9.96B
Levered Free Cash Flow (TTM) i$11.15B$7.50B
Dividends
Last 12-Month Dividend Yield i5.82%3.30%
Last 12-Month Dividend i$3.11$12.18

Valuation & Enterprise Metrics Analysis: Bristol-Myers Squibb Company vs Amgen Inc.

MetricBMY (Apr 26, 2026)AMGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i17.0624.22
Forward P/E i9.6114.77
PEG Ratio i0.010.22
Price to Sales (TTM) i2.505.06
Price to Book (MRQ) i6.5121.46
Market Capitalization
Market Capitalization i$119.87B$187.93B
Enterprise Value i$156.74B$232.21B
Enterprise Value Metrics
Enterprise to Revenue i3.256.32
Enterprise to EBITDA i8.2013.97
Risk & Other Metrics
Beta i0.270.47
Book Value per Share (MRQ) i$9.07$16.07

Financial Statements Comparison: Bristol-Myers Squibb Company vs Amgen Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBMY (2025)AMGN (2025)
Revenue/Sales i48.20B36.75B
Cost of Goods Sold i13.94B12.04B
COGS % of Revenue i28.9%32.8%
Gross Profit i34.26B24.71B
Gross Margin i71.1%67.2%
Research & Development i9.95B7.27B
Operating Income (EBIT) i13.72B9.08B
Operating Margin i28.5%24.7%
EBITDA i19.95B16.90B
EBITDA Margin i41.4%46.0%
Pre-Tax Income i9.33B8.98B
Pre-Tax Income % of Revenue i19.4%24.4%
Income Tax i2.27B1.27B
Income Tax % of Revenue i4.7%3.4%
Net Income (Profit) i7.06B7.71B
Profit Margin i14.6%21.0%

Balance Sheet & Liquidity Metrics

MetricBMY (2025)AMGN (2025)
Cash & Equivalents i10.21B9.13B
Total Current Assets i29.39B29.06B
Total Current Assets % of Revenue i61.0%79.1%
Total Current Liabilities i23.42B25.49B
Total Current Liabilities % of Revenue i48.6%69.4%
Long-Term Debt i44.68B50.01B
Long-Term Debt % of Revenue i92.7%136.1%
Total Shareholders Equity i18.51B8.66B
Retained Earnings i16.90B-25.11B
Retained Earnings % of Revenue i35.1%-68.3%
Property, Plant & Equipment i1.58B5.22B

Cash Flow Statement Comparison

MetricBMY (2025)AMGN (2025)
Operating Cash Flow i14.51B10.51B
Operating Cash Flow % of Revenue i30.1%28.6%
Capital Expenditures iN/A-1.86B
Free Cash Flow i12.85B8.10B
FCF Margin i26.7%22.0%
Debt Repayment i-10.94B-5.00B
Common Stock Repurchase i00

Short Interest & Institutional Ownership Analysis

MetricBMYAMGN
Shares Short i31.50M13.98M
Short Ratio i2.295.43
Short % of Float i1.54%2.60%
Shares Outstanding i2.04B538.80M
Float Shares i2.03B537.62M
% Held by Insiders i0.09%0.22%
% Held by Institutions i83.86%85.36%
% Held by Public i16.05%14.42%

Dividend Analysis & Yield Comparison: Bristol-Myers Squibb Company vs Amgen Inc.

MetricBMYAMGN
Last 12-Month Dividend i$3.11$12.18
Last 12-Month Dividend Yield i5.82%3.30%
3-Year Avg Annual Dividend i$2.60$9.98
3-Year Avg Dividend Yield i1.13%0.77%
3-Year Total Dividends i$7.79$29.95
Ex-Dividend DateJan 02, 2026May 15, 2026